2023
DOI: 10.1007/s11936-023-00979-4
|View full text |Cite
|
Sign up to set email alerts
|

Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure

Abstract: Purpose of review To examine the emerging data for novel strategies being studied to improve use and dose titration of guideline-directed medical therapy (GDMT) for patients with heart failure (HF). Recent findings There is mounting evidence to employ novel multi-pronged strategies to address HF implementation gaps. Summary Despite high-level randomized evidence and clear national society recommendations, a large gap persists in use and dose … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 68 publications
0
4
0
Order By: Relevance
“…A full set of search terms and strategies for each database can be found in eMethods in the Supplement. Sources from related reviews were also screened for possible inclusion …”
Section: Methodsmentioning
confidence: 99%
“…A full set of search terms and strategies for each database can be found in eMethods in the Supplement. Sources from related reviews were also screened for possible inclusion …”
Section: Methodsmentioning
confidence: 99%
“…Finally, guidelines and recommendations pose a challenge to the optimization of treatment because they are not particularly patient-centred and do not necessarily acknowledge the challenges of a real-world population. 72,73 Hence, understanding and addressing these components might improve overall outcomes of patients with HFrEF.…”
Section: Factors Associated With Suboptimal Treatment: Potential Caus...mentioning
confidence: 99%
“…As of 2022, the most proposed modern pharmacologic therapies consist of a comprehensive four drug regimen consisting of beta-blockers, sodium-glucose cotransporter-2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitors(ARNI) 1 .…”
Section: Introductionmentioning
confidence: 99%